Monteverde & Associates PC, a top-ranked class action law firm, is investigating the proposed sale of Option Care Health, Inc. to an investor group including Clayton, Dubilier & Rice and McKesson Corporation. The deal offers Option Care shareholders $32.05 per share in cash. The firm is assessing whether this price is fair and encourages shareholders to seek free legal advice if they have concerns. Monteverde & Associates has a strong track record of recovering money for shareholders in securities class actions.
Option Care Health investigation news is the subject, with Pluang's health sector data providing context. For readers following health stocks, here is Pluang's market snapshot as of Oct 11, 2026 23:11 WIB: Of 128 priced US health stocks, 109 rose and 18 fell. Notable movers include INO at USD 1.15 (+5.50%), BNTX at USD 96.96 (+5.32%), and ILMN at USD 278.17 (+5.21%) with 100% buy order activity on Pluang.
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
Remittix announced its final presale price for the RTX token at $0.46, set as the minimum exchange launch price for its market debut on November 24, 2026. Currently, RTX is available at $0.23 during the ongoing presale stage, with the project nearing...
Ethereum hovered around $2,500 on October 11 after a volatile week marked by a broad crypto selloff impacting major assets like Bitcoin and Solana. Analysts highlight the $2,550–$2,600 range as a critical resistance level for Ethereum, with a potenti...
Volkswagen CEO Oliver Blume called on European policymakers to create supportive frameworks for the automaker's major restructuring amid intense competition from Chinese electric vehicle makers expanding in Europe. At the Paris motor show event, Blum...
Monteverde & Associates PC, a top class action law firm, is investigating the proposed sale of Pacira BioSciences to Viatris Inc., where Pacira shareholders are set to receive $36.50 per share in cash. The firm is questioning whether this deal is fai...
